Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00823472
Other study ID # LITE study
Secondary ID CCMO: NL23705041
Status Terminated
Phase Phase 4
First received
Last updated
Start date January 2009
Est. completion date October 2010

Study information

Verified date January 2019
Source UMC Utrecht
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background of the study:

Milder stimulation protocols have the advantage of being less expensive and more patient-friendly. Moreover, recent evidence suggests that mild stimulation protocols lead to lower embryo aneuploidy rates compared to conventional treatment regimens. Although with mild stimulation protocols the expected number of oocytes retrieved will be lower, pregnancy rates have shown to be similar possibly because embryo quality outfavours embryo quantity.

Objective of the study:

The aim of the study is to determine whether cycle day (CD) 5 start of stimulation will lead to better quality of embryos, based on morphology, than CD 2 start, in IVF with GnRH antagonist co-treatment started on a fixed day.

Study design:

Prospective randomized trial comparing two different starting days of ovarium stimulation (day 2 versus day 5) for IVF treatment.

Intervention:

One group wil start on cycle day 2 with stimulation of the ovaries with recombinant FSH. The other group will start on cycle day 5. Both group will start suppressing the gonadotrophin production of the the pituitary gland on cycle day 6 with a GnRH antagonist.

Primary study parameters/outcome of the study:

Primary outcome parameter is number of top embryos per ovum pick up.

Secondary study parameters/outcome of the study:

Secondary outcome measures are duration of stimulation, cancellation rate, fertilization rate, number of cumulus oocyte complexes obtained, number of mature oocytes obtained, number of top embryos per started cycle, amount of IU recFSH, and clinical pregnancy rate.


Recruitment information / eligibility

Status Terminated
Enrollment 147
Est. completion date October 2010
Est. primary completion date October 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 36 Years
Eligibility Inclusion Criteria:

- Female age < 36 years

- FSH < 12 IU/l

- BMI 18-29 kg/m2

- Regular cycle (25-35 days)

- No major uterine or ovarian abnormalities

- No previous IVF cycles

- Written informed consent

Exclusion Criteria:

- Oocyte donation

- Medical contra indication for pregnancy or IVF treatment

- Endometriosis = grade 3

- Polycystic Ovarium Syndrome (PCOS)

- Endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Mild stimulation
Fixed daily dose of 150 IU rFSH start cycle day 5 or day 2 depending on the Arm

Locations

Country Name City State
Belgium UZ Brussel Brussel
Netherlands University Medical Center Utrecht Utrecht

Sponsors (2)

Lead Sponsor Collaborator
UMC Utrecht Free University Medical Center

Countries where clinical trial is conducted

Belgium,  Netherlands, 

References & Publications (1)

Hohmann FP, Macklon NS, Fauser BC. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab. 2003 Jan;88(1):166-73. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of Top Embryos Per OPU. Proportion of top embryos per ovum pick-up 1 year
Secondary Number of Cumulus Oocyte Complexes Obtained Number of cumulus oocyte complexes obtained after ovum pick-up one year
See also
  Status Clinical Trial Phase
Completed NCT00696878 - Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714) Phase 3
Recruiting NCT04122729 - N680S Polymorphism of the FSHR Gene and Its Relationship With the Type of Gonadotropin Used in COS
Not yet recruiting NCT02534857 - A Study Comparing a Shorter Exposure of Oocyte to Spermatozoa Versus a Standard Incubation on the Live Birth Rate of In-vitro Fertilization Treatment N/A
Recruiting NCT01406600 - Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles N/A
Completed NCT01406028 - Does Emotional Support Decrease In Vitro Fertilization Stress? N/A
Withdrawn NCT00541892 - Sibling Oocyte Study of Medium for In Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) With no Human Serum Albumine Phase 2
Completed NCT00708383 - in Vitro Fertilization (IVF) Media Protein and Live Birth Rates N/A
Completed NCT03627533 - The Differences of Oocyte Maturation, Granulosa Cell Apoptosis Index Between Electroacupuncture And Sham Groups IVF N/A
Recruiting NCT04160611 - What Amount of Stress is Enough for a Successful Conception? Phase 3
Suspended NCT01600794 - To Evaluate The Anrogens and Ovary Function in In Vitro Fertilization N/A
Completed NCT01507376 - Comparing the Efficacy of Urinary and Recombinant Human Chorionic Gonadotropin (hCG) on Oocyte Maturity Phase 3
Terminated NCT00866008 - A Study of the Effects of a Novel Ovarian Stimulation Regimen on Embryo Aneuploidy Rates in In Vitro Fertilization (IVF) Phase 4
Recruiting NCT04082650 - Vitamin D and Pregnancy Outcome in PCOS Patients N/A
Recruiting NCT03758833 - eSET or eDET Associated to PGT in IVF N/A
Not yet recruiting NCT04407871 - Acupuncture and Chinese Herbal Medicine to Improve Live Birth Rate of in Vitro Fertilization (IVFAct) N/A
Recruiting NCT03345030 - The Role of DNA Damage of Granulosa Cell on Oocyte Quality and in Vitro Fertilization Outcome N/A
Not yet recruiting NCT06367985 - CAPA-IVM Culture With Low Oxygen Tension N/A
Not yet recruiting NCT03090438 - IVF Outcomes After Varicocele Repair N/A
Terminated NCT01614067 - Delayed Start to Ovarian Stimulation Phase 4
Completed NCT01343992 - Bed Rest or no Bed Rest? N/A